Inflammatory Markers and Risk for Cognitive Decline in Chronic Kidney Disease: The CRIC Study  by Kurella Tamura, Manjula et al.
CLINICAL RESEARCHCorre
Alto H
fornia
Recei
Octob
KidneyInﬂammatory Markers and Risk
for Cognitive Decline in Chronic
Kidney Disease: The CRIC Study
Manjula Kurella Tamura1,2, Karman Tam1, Eric Vittinghoff3, Dominic Raj4,
Stephen M. Sozio5, Sylvia E. Rosas6, Gail Makos7, Claudia Lora8, Jiang He9, Alan S. Go10,
Chi-yuan Hsu11 and Kristine Yaffe3,12, for the CRIC Study Investigators
1VA Palo Alto Geriatric Research and Education Clinical Center, Palo Alto, California, USA; 2Division of Nephrology, Stanford
University School of Medicine, Palo Alto, California, USA; 3Department of Epidemiology and Biostatistics, University of Cali-
fornia San Francisco, San Francisco, California, USA; 4Division of Renal Disease and Hypertension, GeorgeWashington School
of Medicine, Washington, DC, USA; 5Division of Nephrology, Johns Hopkins University School of Medicine and Welch Center
for Prevention, Epidemiology, and Clinical Research, Baltimore, Maryland, USA; 6Joslin Diabetes Center, Harvard Medical
School, Boston, Massachusetts, USA; 7St. John Providence Medical Center, Detroit, Michigan, USA; 8Division of Nephrology,
University of Illinois College of Medicine, Chicago, Illinois, USA; 9Tulane University School of Public Health and Tropical
Medicine, New Orleans, Louisiana, USA; 10Division of Research, Kaiser Permanente Northern California; Oakland, California,
USA; 11Division of Nephrology, University of California San Francisco, San Francisco, California, USA; and 12Departments of
Psychiatry and Neurology, University of California San Francisco, San Francisco, California, USAIntroduction: Chronic kidney disease (CKD) is associated with an increased risk of cognitive decline, but
the mechanisms remain poorly deﬁned. We sought to determine the relation between serum inﬂamma-
tory markers and risk of cognitive decline among adults with CKD.
Methods: We studied 757 adults aged $55 years with CKD participating in the Chronic Renal Insufﬁciency
Cohort Cognitive study. We measured interleukin (IL)1b, IL-1 receptor antagonist, IL-6, tumor necrosis
factor (TNF)a, high-sensitivity C-reactive protein (hs-CRP), and ﬁbrinogen in baseline plasma samples.
We assessed cognitive function at regular intervals in 4 domains and deﬁned incident impairment as a
follow-up score more than 1 SD poorer than the group mean.
Results: The mean age of the sample was 64.3  5.6 years, and the mean follow-up was 6.2  2.5 years. At
baseline, higher levels of each inﬂammatorymarkerwere associatedwithpoorer age-adjustedperformance.
In analyses adjusted for baseline cognition, demographics, comorbid conditions, and kidney function, par-
ticipants in thehighest tertile of hs-CRP, the highest tertile ofﬁbrinogen, and thehighest tertile of IL-1bhadan
increased risk of impairment in attention compared to participants in the lowest tertile of each marker.
Participants in the highest versus lowest tertile of TNF-a had a lower adjusted risk of impairment in executive
function. There was no association between other inﬂammatory markers and change in cognitive function.
Discussion: Among adults with CKD, higher levels of hs-CRP, ﬁbrinogen, and IL-1b were associated with a
higher risk of impairment in attention. Higher levels of TNF-awere associated with a lower risk of impaired
executive function.
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International Reports (2016) -, -–-suggesting that they have a common pathogenesis. Yet,
in most studies, traditional vascular risk factors do not
appear to attenuate the excess risk of cognitive decline
among patients with CKD.1–3 Inﬂammation is impli-
cated in many vascular diseases and has been suggested
as a mediator of cognitive decline in patients with CKD.
The nature of the association between inﬂammation
and CKD may be bidirectional; that is, inﬂammation
may be both a cause and a consequence of CKD.4,5
Inﬂammation has also been identiﬁed in experi-
mental studies of dementia.6 However, it remains1
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tive role in the pathogenesis of dementia or whether it
is merely an epiphenomenon, as epidemiologic studies
have produced mixed ﬁndings.7–12 Many of these
studies evaluated only 1 or 2 inﬂammatory markers.
Consequently, they provide an incomplete picture of
the systemic inﬂammatory state and its relation to
cognitive decline. The intensity of systemic inﬂamma-
tion, as indicated by elevations in multiple markers of
inﬂammation, including interleukin-1b (IL-1b),
interleukin-6 (IL-6), tumor necrosis factora (TNF-a),
and C-reactive protein (CRP), appears to increase as
kidney function declines.13,14
Therefore, studying patients with CKD might pro-
vide more speciﬁc insight into the relation between
inﬂammation and cognitive decline related to vascular
causes, as CKD is more strongly associated with
vascular dementia than Alzheimer’s disease.1,2 In 2
cross-sectional studies of patients with CKD, the
inﬂammatory markers interleukin-10, CRP, and ﬁbrin-
ogen correlated with the presence of cognitive
impairment.15,16 To our knowledge, no studies have
prospectively evaluated the association of systemic
inﬂammatory markers with cognitive decline among
patients with CKD.
We aimed to determine whether systemic inﬂam-
matory markers were independently associated with
cognitive decline in patients with CKD. To address
this question, we measured plasma levels of multiple
inﬂammatory cytokines and acute phase reactants in a
subset of adults enrolled in the Chronic Renal
Insufﬁciency Cohort (CRIC), a large cohort study of
men and women with CKD. We hypothesized that
elevated levels of inﬂammatory markers would have
independent, additive effects on the risk of cognitive
decline.
METHODS
Study Design and Recruitment
The CRIC Study is a prospective observational cohort
study designed to evaluate risk factors for progression
of CKD.17,18 From June 2003 through May 2008, we
recruited 3939 persons aged 21 to 74 years from 7
clinical centers across the United States. Participants
met age-based estimated glomerular ﬁltration rate
(eGFR) criteria: 20 to 70 ml/min/1.73 m2 for ages 21 to
44 years, 20 to 60 ml/min/1.73 m2 for ages 45 to
64 years, and 20 to 50 ml/min/1.73 m2 for ages 65 to
74 years. Exclusion criteria included diagnosis of
polycystic kidney disease, pregnancy, recent immu-
nosuppression for kidney disease, coexisting disease
likely to affect survival, prior receipt of dialysis or
organ transplant, residence in nursing homes, or
inability to provide consent. Beginning in 2006, a total2of 825 participants aged 55 years or older from 4 of the
7 CRIC centers were enrolled in a cognitive ancillary
study (the CRIC COG Study). Of these 825 participants,
18 were excluded from the analysis because they had
end-stage renal disease at the CRIC COG baseline visit.
Of the remaining participants, 761 had measurement of
inﬂammatory markers at baseline and at least 1 cogni-
tive follow-up assessment. We excluded 4 participants
missing important covariates, leaving 757 participants
in the analytic cohort.
Ethics, Consent, and Permissions
Institutional review boards at all clinical sites approved
the study protocol, and all participants provided
written informed consent.
Measurement of Cognitive Function
Participants in CRIC COG underwent a battery of
cognitive function tests.19 Tests were administered
annually for the ﬁrst 4 years and then biannually
thereafter. The ModiﬁedMini Mental State Examination
(3MS) is a test of global cognitive function with com-
ponents for concentration, orientation, language, praxis,
and memory.20 The Trailmaking Test A (Trails A) mea-
sures attention, visuospatial scanning, and motor speed.
The Trailmaking Test B (Trails B) primarily assesses ex-
ecutive function.21 The Buschke Selective RemindingTest
measures verbalmemorywith delayed components.22 The
mean follow-up time was 6.2  2.5 years.
Measurement of Inﬂammatory Markers
Inﬂammatory markers were measured a median of 1.2
(interquartile ratio [IQR] ¼ 0.9, 2.0) years before the
baseline cognitive assessment. We used high-sensitivity
sandwich enzyme-linked immunosorbent assays to
measure TNF-a, IL-1b, and IL-6 levels, and standard
sandwich enzyme-linked immunosorbent assays to
measure IL-1RA (Quantikine, R&D Systems, Minneap-
olis, MN), as previously described.14 We quantiﬁed hs-
CRP and ﬁbrinogen from ethylenediaminetetraacetic
acid (EDTA)treated plasma samples using laser-based
immunonephelometric methods on the BNII nephelom-
eter (Siemens Healthcare, Mountain View, CA). All as-
says were performed in duplicate, and mean values were
used for analysis. Inﬂammatory markers were analyzed
as tertiles.
Covariates
Sociodemographic and clinical characteristics were
assessed at the cognitive baseline visit. We deﬁned
diabetes by participant self-report, use of medications
for diabetes, or fasting blood glucose of $126 mg/dl.
We deﬁned hypertension by participant self-report,
use of medications for high blood pressure, or a
seated blood pressure of $140/80 mm Hg. We deﬁnedKidney International Reports (2016) -, -–-
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myocardial infarction, angina, stroke, claudication,
amputation, or revascularization procedure of the
coronaries or the extremities. We deﬁned tobacco
use as current versus former or never use. We calcu-
lated the estimated glomerular ﬁltration rate (eGFR)
with an equation derived from the CRIC Study,
using the annual serum creatinine and cystatin C
measurements corresponding to the ﬁrst cognitive
function assessment.23 Urine albumin and creatinine
were measured on spot urine samples and categorized
as <30 mg/g, $30 mg/g, or missing for analysis.
Statistical Analysis
Continuous variables were expressed as mean  SD
or median (intertertile range), and categorical variables
were expressed as proportions. We ﬁrst examined the
age-adjusted baseline association between inﬂamma-
tory markers and cognitive function, expressed as the
percent difference in cognitive score relative to that of
patients in the lowest tertile of each inﬂammatory
marker. Next, we determined the association between
inﬂammatory markers and longitudinal changes in
cognitive scores on each test, using mixed effects
models with unstructured residual correlation matrix
to account for within-subject correlation. Cognitive
test scores were log-transformed for analysis, and then
back-transformed for ease of interpretation. We ﬁrst
adjusted for age, sex, race, ethnicity, education, and
CRIC clinical center (minimally adjusted model). Next,
we adjusted for baseline comorbid conditions,
including some factors that may lie in the causal
pathway: diabetes, hypertension, cardiovascular dis-
ease, smoking, eGFR, and albuminuria (multivariable
adjusted model). Interactions of inﬂammatory marker
tertile with time were used to capture the association
of the markers with change in cognitive function,
with a test for linear trend across tertiles. Because the
minimally adjusted and multivariable adjusted models
were similar, multivariable adjusted models are pre-
sented. In sensitivity analyses, we censored observa-
tions after the development of end-stage renal disease.
We also jointly modeled the outcomes of cognitive
decline and time to death or loss to follow-up with
shared random effects, to assess whether informative
censoring of the cognitive function measures materi-
ally changed the results.24
In complementary analyses, we constructed Cox
proportional hazards models to determine the associa-
tion between tertiles of each inﬂammatory marker and
the incidence of cognitive impairment, deﬁned as a test
score during follow-up more than 1 SD worse than the
group mean at baseline. Individuals with cognitive
impairment at the baseline examination were excludedKidney International Reports (2016) -, -–-from these analyses. Adjusted models included the
baseline cognitive test score in addition to age, sex,
race, ethnicity, education, CRIC clinical center, dia-
betes, hypertension, cardiovascular disease, smoking,
eGFR, and albuminuria. We repeated the models
applying a Bonferroni corrected P value of 0.002 to
account for multiple comparisons (0.05/[6 inﬂammatory
markers  4 cognitive tests]).
Finally, to assess whether there were additive effects
among the inﬂammatory markers, we constructed an
inﬂammatory load score, consisting of the number of
inﬂammatory markers in the highest tertile. We
compared 2 scores, 1 consisting of IL-1b, hs-CRP, and
ﬁbrinogen, the markers with the strongest associations
with cognitive decline, to a score consisting of all
inﬂammatory markers.
RESULTS
Baseline Cohort Characteristics
The mean age of the sample was 64.3  5.6 years, and
mean estimated glomerular ﬁltration rate (eGFR) was
43.2  16.3 ml/min/1.73 m2. The sample included 386
men (51.0%), 379 participants of white race/ethnicity
(50.1%), and 383 participants with diabetes (50.6%).
The median and intertertile ranges for each inﬂam-
matory marker and mean (SD) baseline cognitive test
scores are presented in Table 1. IL-b was correlated
with IL-1 receptor antagonist (IL-1RA) (r ¼ 0.48,
P < 0.01). In addition, hs-CRP was correlated
with ﬁbrinogen (r ¼ 0.38, P < 0.01), and weakly
correlated with IL-1RA (r ¼ 0.12, P < 0.01). There
was no correlation among the other inﬂammatory
markers.
Higher levels of each inﬂammatory marker were
associated with poorer age-adjusted cognitive test
scores at baseline (Figure 1). Relative to the scores of
participants in the lowest tertile for each inﬂammatory
marker, the percentage difference in cognitive test
scores were largest for the 3MS, Trails A tests, and
Trails B tests, and less pronounced for the Buschke
Selective Reminding Test.
Inﬂammatory Markers and Change in Cognitive
Function
The mean annual percentage change in cognitive func-
tion over 6.2  2.5 years of follow-up was small.
Mean declines in cognitive function were observed
on the 3MS (1.18%, 95% conﬁdence interval
[CI] ¼ 1.92%, 0.44%) and Trails B (0.53%, 95%
CI ¼ 0.92%, 0.13%) tests, whereas cognitive per-
formance improved slightly over time on the Trails A
(0.51%, 95% CI¼ 0.10%, 0.92%) and Buschke (0.82%,
95% CI ¼ 0.38%, 1.27%) tests (Table 2). There was no
signiﬁcant linear association between tertiles of3
Table 1. Characteristics of 757 CRIC participants with measurement
of inﬂammatory markers and cognitive function
Characteristic n (%)
Age, yr
50–59 175 (23.1)
60–69 419 (55.4)
$70 163 (21.5)
Sex
Male 386 (51.0)
Female 371 (49.0)
Race
White 379 (50.1)
Black 325 (42.9)
Other/unknown 53 (7.0)
Hispanic ethnicity
Hispanic 21 (2.8)
Other/unknown 736 (97.2)
Education
<High school 108 (14.3)
High school graduate 155 (20.5)
Some college 494 (65.3)
Diabetes mellitus 383 (50.6)
Hypertension 687 (90.8)
Prior cardiovascular disease 290 (38.3)
Current smoker 79 (10.4)
eGFR CRIC, ml/min/1.73 m2
$60 124 (16.4)
45 to <60 211 (27.9)
30 to <45 255 (33.7)
<30 167 (22.1)
Albuminuria (mg/g)
<30 351 (46.4)
>30 381 (50.3)
Unknown 25 (3.3)
Inﬂammatory markers Median (P33, P67)
IL-1b (pg/ml) 0.06 (0.06, 0.48)
IL-1RA (pg/ml) 634.1 (422.7, 1026.8)
TNF-a (pg/ml) 2.00 (1.60, 2.60)
IL-6 (pg/ml) 1.92 (1.39, 2.52)
hs-CRP (mg/L) 2.47 (1.35, 4.41)
Fibrinogen (g/L) 4.00 (3.59, 4.45)
Cognitive function Mean (SD)
3MS 93.15 (7.36)
Trails A 54.29 (36.57)
Trails B 136.95 (77.68)
Buschke Selective Reminding Test 7.44 (2.93)
CRIC, Chronic Renal Insufﬁciency Cohort; eGFR, estimated glomerular ﬁltration rate;
hs-CRP, high sensitivity C-reactive protein; IL, interleukin; 3MS, Modiﬁed Mini Mental
State Examination; TNF, tumor necrosis factor.
Note: Inﬂammatory markers are presented as median (33rd, 67th) percentiles.
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in minimally adjusted models (Supplementary Table S1).
In multivariable adjusted models, there was a signiﬁcant
linear trend for larger improvement on the Buschkewith
higher levels of ﬁbrinogen (Table 2). There was no evi-
dence for a linear trend across inﬂammatory marker
tertiles on other cognitive tests. Compared to partici-
pants in the lowest tertile, participants with IL-1RA
levels in the middle tertile experienced more rapid
cognitive decline on the 3MS, but this did not reach4statistical signiﬁcance for participants in the highest
tertile of IL-1RA. Compared to participants in the lowest
tertile, participants in the middle tertile of TNF-a
experienced signiﬁcantly slower decline on the 3MS, but
this did not reach signiﬁcance for participants in the
highest tertile. We observed a similar pattern in models
censoring patients at end-stage renal disease and in joint
models for change in cognitive function and time to
death or loss to follow-up (Supplementary Table S2).
Inﬂammatory Markers and Incident Cognitive
Impairment
During follow-up, the incidence of impairment ranged
between 13.1% on the Trails A test to 19.8% on the
Trails B test (Table 3). The associations between
inﬂammatory markers and incident cognitive impair-
ment were consistent with the direction of the parameter
estimates from the models evaluating change in cogni-
tive function. In multivariable adjusted models, partic-
ipants with hs-CRP in the highest tertile, and
participants with ﬁbrinogen levels in the highest tertile
had more than a 2-fold higher adjusted risk of incident
impairment on the Trails A test compared to participants
in the lowest tertile of each marker. In addition, partic-
ipants in the highest tertile of IL-1b had a borderline
nonsigniﬁcant increased risk of impairment on the Trails
A compared to participants in the lowest tertile.
Compared to participants in the lowest tertile of IL-1RA,
participants with IL-1RA levels in the middle tertile had
a borderline nonsigniﬁcant higher adjusted risk of
incident impairment on the 3MS, but this did not reach
signiﬁcance for participants in the highest tertile.
Conversely, participantswith TNF-a levels in the second
or third tertile had a lower adjusted risk of incident
impairment on the Trails B test compared to participants
in the lowest tertile. These associations were not statis-
tically signiﬁcant after accounting for multiple com-
parisons (Supplementary Table S3).
Compared to participants without elevated levels of
IL-1b, hs-CRP, or ﬁbrinogen, there was a borderline
higher risk of impairment on the Trails A test for par-
ticipants with 1 elevated marker (hazard ratio [HR] ¼
1.72, 95% CI¼ 0.91, 3.26), and signiﬁcantly higher risk
for participants with 2 or more elevated inﬂammatory
markers (HR ¼ 3.21, 95% CI ¼ 1.71, 6.01) after adjust-
ment for baseline cognitive function, demographic
characteristics, comorbid conditions, and kidney func-
tion. There was no signiﬁcant association between
inﬂammatory load and other cognitive tests. In com-
parison, when the inﬂammatory load score included all
inﬂammatory markers, the risk of impairment on the
Trails A test was signiﬁcantly higher for participants
with 2 elevated inﬂammatory markers (HR ¼ 2.35, 95%
CI ¼ 1.06, 5.22), and 3 or more elevated inﬂammatoryKidney International Reports (2016) -, -–-
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Figure 1. Adjusted percent difference in baseline cognitive scores by inﬂammatory marker.
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participants with no elevated inﬂammatory markers.
DISCUSSION
In a large cohort of adults with CKD, higher levels of
multiple systemic inﬂammatory markers were associ-
ated with poorer baseline cognitive function. In lon-
gitudinal analyses, the association between systemic
inﬂammatory markers and mean change in cognitive
function was small. The strongest associations
between inﬂammatory markers and change in cogni-
tive function were observed in the domain of atten-
tion, assessed with the Trails A test. Participants withKidney International Reports (2016) -, -–-the highest levels of hs-CRP or ﬁbrinogen each had
more than a 2-fold increased risk of impairment in
attention compared to participants with the lowest
levels, independent of multiple potential confounders,
whereas participants in the highest tertile of IL-1b had
a similar but nonsigniﬁcant higher risk of impairment
in attention. In addition, participants with elevated
levels of 2 or more of these inﬂammatory markers had
more than a 3-fold increased risk of impairment in
attention. Perhaps unexpectedly, participants with
higher levels of TNF-a were at lower risk for
impairment in executive function, assessed with the
Trails B test.5
Table 2. Adjusted association of inﬂammatory markers with change in cognitive function
Parameter estimate (95% conﬁdence interval)
3MS Trails A Trails B Buschke Selective Reminding
Mean annual change, % –1.18 (–1.92, –0.44) 0.51 (0.10, 0.92) –0.53 (–0.92, –0.13) 0.82 (0.38, 1.27)
IL-1b, pg/ml
Tertile 2  time 0.17 (–1.97, 2.26) 1.05 (–0.16, 2.25) –0.08 (–1.28, 1.11) 0.31 (–1.02, 1.66)
Tertile 3  time –1.13 (–2.90, 0.60) –0.30 (–1.30, 0.69) 0.01 (–0.96, 0.98) –0.25 (–1.32, 0.83)
P value for trend 0.20 0.55 0.98 0.64
IL-1RA, pg/ml
Tertile 2  time --2.17 (--3.97, --0.41) 0.23 (–0.78, 1.22) 0.55 (–0.43, 1.52) –0.16 (–1.25, 0.94)
Tertile 3  time –1.50 (–3.36, 0.32) –0.40 (–1.45, 0.64) 0.10 (–0.92, 1.11) –0.43 (–1.56, 0.71)
P value for trend 0.11 0.45 0.85 0.46
TNF-a, pg/ml
Tertile 2  time 1.82 (0.04, 3.56) 0.41 (–0.62, 1.42) 0.40 (–0.60, 1.39) 0.65 (–0.46, 1.77)
Tertile 3  time 1.31 (–0.66, 3.23) 0.48 (–0.65, 1.60) 0.28 (–0.82, 1.38) 0.75 (–0.48, 1.99)
P value for trend 0.19 0.40 0.61 0.23
IL-6, pg/ml
Tertile 2  time 0.53 (–1.28, 2.30) –0.47 (–1.50, 0.56) –0.54 (–1.55, 0.46) –0.23 (–1.35, 0.89)
Tertile 3  time 0.12 (–1.81, 2.01) –0.32 (–1.42, 0.77) –0.01 (–1.08, 1.05) 0.56 (–0.62, 1.76)
P value for trend 0.91 0.57 0.99 0.36
hs-CRP (mg/L)
Tertile 2  time –0.38 (–2.12, 1.34) –0.52 (–1.51, 0.46) –0.56 (–1.53, 0.40) –0.50 (–1.56, 0.57)
Tertile 3  time –1.23 (–3.08, 0.57) –0.19 (–1.23, 0.84) 0.15 (–0.87, 1.15) 0.15 (–0.98, 1.28)
P value for trend 0.18 0.72 0.78 0.80
Fibrinogen, g/l
Tertile 2  time 0.02 (–1.73, 1.74) 0.03 (–0.97, 1.01) 0.42 (–0.54, 1.37) 0.37 (–0.71, 1.45)
Tertile 3  time 0.02 (–1.89, 1.89) –0.66 (–1.76, 0.42) 0.22 (–0.84, 1.26) 1.37 (0.19, 2.58)
P value for trend 0.98 0.23 0.69 0.02
hs-CRP, high sensitivity C-reactive protein; IL, interleukin; 3MS, Modiﬁed Mini Mental State Examination; TNF, tumor necrosis factor.
Parameter estimates represent percent change in cognitive function tests per year, relative to the referent group in the lowest tertile of each inﬂammatory marker. A negative parameter
estimate indicates poorer cognitive function over time relative to the referent group.
Models are adjusted for age, sex, race, ethnicity, education, Chronic Renal Insufﬁciency Cohort (CRIC) center, diabetes, hypertension, cardiovascular disease, smoking, estimated
glomerular ﬁltration rate, and albuminuria. Parameter estimates in bold are statistically signiﬁcant (P < 0.05).
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when interpreting these results. We assessed change in
cognitive function in 2 ways: as a continuous measure
and as a dichotomous outcome incident cognitive
impairment, the latter to capture large declines in
cognitive function that are likely to be clinically
important. Although the 2 approaches yielded results
that were generally consistent, several inﬂammatory
markers had stronger associations with incident
impairment than with change in cognitive function, a
result that is similar to a previous study of inﬂamma-
tory markers in patients without CKD.8 This might
imply that the association between inﬂammation and
cognitive decline is not uniform across the spectrum of
cognitive function. Along the same lines, measurement
error may have a larger relative effect on small changes
in cognitive function.8 Participants with high levels of
inﬂammatory markers may also be at higher risk for
death, which might lead to an underestimation of the
association between inﬂammatory markers and change
in cognitive function. However, our ﬁndings were
robust to analyses that accounted for death or follow-
up loss. We assessed each cognitive test as a separate
outcome because each taps a different cognitive6domain. This approach allowed us to evaluate whether
inﬂammatory markers were associated with decline in
speciﬁc domains, but increases the likelihood of a false-
positive ﬁnding. When we used the Bonferroni method
to account for multiple comparison, the ﬁndings did
not reach statistical signiﬁcance; thus the positive
ﬁndings in the main analysis should be interpreted
with caution. This method of correcting for multiple
comparisons has been criticized for being too conser-
vative, because it assumes that the outcomes are
independent.
The most studied inﬂammatory marker is the acute
phase reactant CRP. In a meta-analysis of 7 studies in
populations without CKD, higher levels of CRP were
associated with an increased risk of dementia,
including vascular dementia.25 Several but not all
studies in the general population have also demon-
strated a relationship between elevated CRP levels and
cognitive decline.9,10 In a cross-sectional study of
Mexican Americans with CKD, Szerlip et al. found that
a serum proteomic proﬁle including CRP was correlated
with the prevalence of cognitive impairment; however,
the strength of the association for CRP individually was
not reported.15Kidney International Reports (2016) -, -–-
Table 3. Adjusted risk of incident cognitive impairment among adults with chronic kidney disease
Hazard ratio (95% conﬁdence interval)
3MS Trails A Trails B Buschke Selective Reminding
n (%) with impairment 92 (13.9) 85 (13.1) 121 (19.8) 105 (16.9)
IL-1b, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.86 (0.43, 1.72) 1.16 (0.59, 2.29) 0.63 (0.31, 1.27) 1.18 (0.62, 2.23)
Tertile 3 1.02 (0.60, 1.75) 1.67 (0.97, 2.89) 0.92 (0.57, 1.46) 1.05 (0.64, 1.72)
IL-1RA, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.75 (0.99, 3.10) 1.13 (0.63, 2.03) 1.09 (0.66, 1.78) 1.48 (0.89, 2.45)
Tertile 3 1.26 (0.69, 2.31) 1.37 (0.73, 2.55) 1.05 (0.62, 1.78) 1.56 (0.91, 2.65)
TNF-a, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.92 (0.50, 1.70) 1.47 (0.74, 2.90) 0.56 (0.34, 0.91) 0.98 (0.55, 1.77)
Tertile 3 1.44 (0.75, 2.76) 1.52 (0.74, 3.14) 0.47 (0.27, 0.84) 1.17 (0.64, 2.14)
IL-6, pg/ml
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.32 (0.73, 2.39) 1.08 (0.57, 2.08) 1.38 (0.81, 2.34) 1.13 (0.66, 1.95)
Tertile 3 1.18 (0.63, 2.22) 1.08 (0.56, 2.10) 1.33 (0.77, 2.31) 1.02 (0.58, 1.80)
hs-CRP, mg/l
Tertile 1 (Ref) 1 1 1 1
Tertile 2 1.06 (0.60, 1.87) 0.81 (0.43, 1.51) 1.23 (0.75, 2.02) 1.61 (0.98, 2.64)
Tertile 3 1.45 (0.83, 2.53) 2.27 (1.26, 4.06) 1.29 (0.78, 2.15) 1.09 (0.65, 1.84)
Fibrinogen, g/l
Tertile 1 (Ref) 1 1 1 1
Tertile 2 0.83 (0.48, 1.44) 1.17 (0.60, 2.29) 0.92 (0.55, 1.52) 1.20 (0.72, 1.99)
Tertile 3 0.73 (0.40, 1.33) 2.06 (1.10, 3.84) 1.17 (0.71, 1.93) 0.82 (0.47, 1.45)
hsCRP, high-sensitivity C-reactive protein; IL, interleukin; 3MS, Modiﬁed Mini Mental State Examination; Ref, reference; TNF, tumor necrosis factor.
Models are adjusted for baseline cognitive score, age, sex, race, ethnicity, education, Chronic Renal Insufﬁciency Cohort (CRIC) center, diabetes, hypertension, cardiovascular disease,
smoking, estimated glomerular ﬁltration rate, and albuminuria. Hazard ratios in bold are statistically signiﬁcant (P < 0.05).
M Kurella Tamura et al.: Inﬂammation and Cognitive Decline in CKD CLINICAL RESEARCHFibrinogen is an acute phase reactant involved in the
coagulation cascade. Like CRP, elevated ﬁbrinogen
levels have been linked to cognitive decline and
dementia, including vascular dementia, in populations
without CKD.26,27 Seidel et al. reported that elevated
ﬁbrinogen levels were cross-sectionally correlated with
cognitive impairment in a cohort of 119 patients with
CKD.16
Our results extend the ﬁndings from prior studies,
by demonstrating that CRP and ﬁbrinogen are inde-
pendently associated with longitudinal changes in
some domains of cognitive function in patients with
CKD. Our results suggest that elevated CRP, ﬁbrinogen,
and possibly IL-1b levels are more strongly associated
with incident impairment in attention versus global
cognition or memory (assessed in the current study
with the 3MS and Buschke tests, respectively). This
observation may be due to chance. Alternatively, it
may be consistent with the hypothesis that inﬂamma-
tion contributes to cognitive decline in part through
vascular mechanisms, as impaired attention is more
prominent in vascular causes of dementia than memory
impairment.6
In addition, we found that higher levels of the
inﬂammatory cytokine TNF-a were associated with a
lower risk of impairment in executive function. AmongKidney International Reports (2016) -, -–-patients without CKD, the relation between TNF-a and
cognitive decline has been conﬂicting; although 1
study demonstrated an association between increased
peripheral blood mononuclear cell production of TNF-a
and an increased risk of dementia (speciﬁcally Alz-
heimer’s disease), other studies have not identiﬁed an
association between TNF-a and cognitive decline.9,12
To test the hypothesis that inﬂammatory markers
have additive effects on cognitive function, we con-
structed an inﬂammatory load score as a proxy for the
systemic inﬂammatory state. These results suggest that
IL-1b, hs-CRP, and ﬁbrinogen may have independent,
additive effects on the risk of impairment in attention.
When the inﬂammatory load included all 6 inﬂamma-
tory markers, this association was attenuated, sug-
gesting that IL-1RA, IL-6, and TNF-a did not have
additive effects on the risk of impairment after
accounting for IL-1b, hs-CRP, and ﬁbrinogen.
Strengths of this study include the prospective
design, diverse study population, use of a cognitive
battery to assess cognitive function, and measurement
of multiple inﬂammatory markers, providing a more
complete picture of the systemic inﬂammatory state.
This study also has several limitations. Participants
in CRIC may be at lower risk for cognitive decline than
the broader population with CKD, because they are7
CLINICAL RESEARCH M Kurella Tamura et al.: Inﬂammation and Cognitive Decline in CKDselected for the ability to comply with study visits and
they may be more motivated to pursue healthy
behaviors. Inﬂammatory markers were measured at a
single point in time, a median 1.2 years before the
baseline cognitive test assessment. This lag may have
caused a larger relationship between inﬂammatory
markers and changes in cognitive function to go
unobserved. We cannot rule out the possibility that the
results reﬂect false-positive ﬁndings from conducting
multiple comparisons, as the ﬁndings did not reach
signiﬁcance using a conservative method to account for
multiple comparisons. Finally, because this was an
observational study, residual confounding may have
affected the results.
In conclusion, in a large cohort of adults with CKD,we
found that elevated levels of multiple inﬂammatory
markers were associated with an increased risk of
impairment in attention, whereas elevated levels of TNF-
awere associatedwith a lower risk of impaired executive
function. Additional studies are needed to conﬁrm these
results, and to determine whether treatment of inﬂam-
mation can slow or prevent cognitive decline.
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
The CRIC Study Investigators are as follows:
Lawrence J. Appel, Harold I. Feldman, Alan S. Go,
Jiang He, John W. Kusek, James P. Lash, Akinlolu Ojo,
Mahboob Rahman, and Raymond R. Townsend. Views
expressed are those of the authors and not necessarily
those of the Department of Veterans Affairs.
Funding for the CRIC Study was obtained under a
cooperative agreement from National Institute of Dia-
betes and Digestive and Kidney Diseases (NIDDK)
(U01DK060990, U01DK060984, U01DK061022, U01DK
061021, U01DK061028, U01DK060980, U01DK060963,
and U01DK060902). In addition, this work was sup-
ported in part by: the Perelman School of Medicine
at the University of Pennsylvania Clinical and Trans-
lational Science Award NIH/NCATS UL1TR000003,
Johns Hopkins University UL1 TR-000424, University
of Maryland GCRC M01 RR-16500, Clinical and
Translational Science Collaborative of Cleveland,
UL1TR000439 from the National Center for Advancing
Translational Sciences (NCATS) component of the
National Institutes of Health and NIH roadmap for
Medical Research, Michigan Institute for Clinical and
Health Research (MICHR) UL1TR000433, University
of Illinois at Chicago CTSA UL1RR029879, Tulane
University Translational Research in Hypertension
and Renal Biology P30GM103337, Kaiser Permanente8NIH/NCRR UCSF-CTSI UL1 RR-024131. Funding for the
CRIC COG study is supported by R01DK069406 from
the NIDDK.
SUPPLEMENTARY MATERIAL
Table S1. Minimally adjusted association of inﬂammatory
markers with change in cognitive function
Table S2. Adjusted association of inﬂammatory markers
with change in cognitive function, time to death, or loss
to follow-up
Table S3. Adjusted risk of incident cognitive impairment
among adults with chronic kidney disease, accounting for
multiple comparisons (Bonferroni corrected P ¼ 0.002)
Supplementary material is linked to the online version of
the paper at http://www.kireports.org.
REFERENCES
1. Seliger SL, Siscovick DS, Stehman-Breen CO, et al. Moderate
renal impairment and risk of dementia among older adults:
the Cardiovascular Health Cognition Study. J Am Soc Neph-
rol. 2004;15:1904–1911.
2. Helmer C, Stengel B, Metzger M, et al. Chronic kidney dis-
ease, cognitive decline, and incident dementia: the 3C Study.
Neurology. 2011;77:2043–2051.
3. Kurella M, Chertow GM, Fried LF, et al. Chronic kidney dis-
ease and cognitive impairment in the elderly: the Health,
Aging, and Body Composition Study. J Am Soc Nephrol.
2005;16:2127–2133.
4. Kaysen GA. The microinﬂammatory state in uremia: causes
and potential consequences. J Am Soc Nephrol. 2001;12:
1549–1557.
5. Shankar A, Sun L, Klein BE, et al. Markers of inﬂammation
predict the long-term risk of developing chronic kidney dis-
ease: a population-based cohort study. Kidney Int. 2011;80:
1231–1238.
6. Gorelick PB, Scuteri A, Black SE, et al, American Heart
Association Stroke Council, Council on Epidemiology and
Prevention, Council on Cardiovascular Nursing, Council on
Cardiovascular Radiology and Intervention, and Council on
Cardiovascular Surgery and Anesthesia. Vascular contribu-
tions to cognitive impairment and dementia: a statement
for healthcare professionals from the American Heart
Association/American Stroke Association. Stroke. 2011;42:
2672–2713.
7. Schmidt R, Schmidt H, Curb JD, et al. Early inﬂammation and
dementia: a 25-year follow-up of the Honolulu-Asia Aging
Study. Ann Neurol. 2002;52:168–174.
8. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW,
Seeman TE. Interleukin-6 and risk of cognitive decline: Mac-
Arthur studies of successful aging. Neurology. 2002;59:
371–378.
9. Yaffe K, Lindquist K, Penninx BW, et al. Inﬂammatory markers
and cognition in well-functioning African-American and white
elders. Neurology. 2003;61:76–80.
10. Dik MG, Jonker C, Hack CE, et al. Serum inﬂammatory pro-
teins and cognitive decline in older persons. Neurology.
2005;64:1371–1377.Kidney International Reports (2016) -, -–-
M Kurella Tamura et al.: Inﬂammation and Cognitive Decline in CKD CLINICAL RESEARCH11. Schram MT, Euser SM, de Craen AJ, et al. Systemic markers
of inﬂammation and cognitive decline in old age. J Am Ger-
iatr Soc. 2007;55:708–716.
12. Tan ZS, Beiser AS, Vasan RS, et al. Inﬂammatory markers and
the risk of Alzheimer disease: the Framingham Study.
Neurology. 2007;68:1902–1908.
13. Shlipak MG, Fried LF, Crump C, et al. Elevations of inﬂam-
matory and procoagulant biomarkers in elderly persons with
renal insufﬁciency. Circulation. 2003;107:87–92.
14. Gupta J, Mitra N, Kanetsky PA, et al. Association between
albuminuria, kidney function, and inﬂammatory biomarker
proﬁle inCKDinCRIC.ClinJAmSocNephrol. 2012;7:1938–1946.
15. Szerlip HM, Edwards ML, Williams BJ, et al. Association
between cognitive impairment and chronic kidney disease in
Mexican Americans. J Am Geriatr Soc. 2015;63:2023–2028.
16. Seidel UK, Gronewold J, Volsek M, et al. The prevalence,
severity, and association with HbA1c and ﬁbrinogen of
cognitive impairment in chronic kidney disease. Kidney Int.
2014;85:693–702.
17. Feldman HI, Appel LJ, Chertow GM, et al. The Chronic Renal
Insufﬁciency Cohort (CRIC) Study: design and methods. J Am
Soc Nephrol. 2003;14(7 Suppl 2):S148–S153.
18. Lash JP, Go AS, Appel LJ, et al. Chronic Renal Insufﬁciency
Cohort (CRIC) Study: baseline characteristics and associations
with kidney function.Clin JAmSocNephrol. 2009;4:1302–1311.
19. Yaffe K, Ackerson L, Kurella Tamura M, et al. Chronic Renal
Insufﬁciency Cohort I. Chronic kidney disease and cognitiveKidney International Reports (2016) -, -–-function in older adults: ﬁndings from the chronic renal
insufﬁciency cohort cognitive study. J Am Geriatr Soc.
2010;58:338–345.
20. Teng EL, Chui HC. The Modiﬁed Mini-Mental State (3MS)
examination. J Clin Psychiatry. 1987;48:314–318.
21. Reitan RM. Validity of the Trail Making Test as an indicator of
organic brain damage. Percept Mot Skills. 1958;8:271–276.
22. Buschke H, Fuld PA. Evaluating storage, retention, and
retrieval in disordered memory and learning. Neurology.
1974;24:1019–1025.
23. Anderson AH, Yang W, Hsu CY, et al. Estimating GFR among
participants in the Chronic Renal Insufﬁciency Cohort (CRIC)
Study. Am J Kidney Dis. 2012;60:250–261.
24. Hogan JW, Laird NM. Model-based approaches to analysing
incomplete longitudinal and failure time data. Stat Med.
1997;16:259–272.
25. Koyama A, O’Brien J, Weuve J, et al. The role of peripheral
inﬂammatory markers in dementia and Alzheimer’s disease:
a meta-analysis. J Gerontol A Biol Sci Med Sci. 2013;68:
433–440.
26. van Oijen M, Witteman JC, Hofman A, et al. Fibrinogen is
associated with an increased risk of Alzheimer disease and
vascular dementia. Stroke. 2005;36:2637–2641.
27. Marioni RE, Stewart MC, Murray GD, et al. Peripheral levels of
ﬁbrinogen, C-reactive protein, and plasma viscosity predict
future cognitive decline in individuals without dementia.
Psychosom Med. 2009;71:901–906.9
